1. Home
  2. ACRS vs PMI Comparison

ACRS vs PMI Comparison

Compare ACRS & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

N/A

Current Price

$3.06

Market Cap

230.8M

Sector

Health Care

ML Signal

N/A

PMI

Picard Medical Inc.

N/A

Current Price

$2.29

Market Cap

202.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ACRS
PMI
Founded
2012
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
230.8M
202.7M
IPO Year
2015
2025

Fundamental Metrics

Financial Performance
Metric
ACRS
PMI
Price
$3.06
$2.29
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$9.75
N/A
AVG Volume (30 Days)
1.2M
2.5M
Earning Date
11-06-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,742,000.00
$4,767,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.81
52 Week Low
$1.05
$1.90
52 Week High
$3.48
$13.68

Technical Indicators

Market Signals
Indicator
ACRS
PMI
Relative Strength Index (RSI) 56.89 N/A
Support Level $3.12 N/A
Resistance Level $3.48 N/A
Average True Range (ATR) 0.22 0.00
MACD -0.00 0.00
Stochastic Oscillator 52.54 0.00

Price Performance

Historical Comparison
ACRS
PMI

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About PMI Picard Medical Inc.

Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing an implantable Total Artificial Heart. It is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including TAH. The TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.

Share on Social Networks: